Is There a Role for Novel BCMA-Directed Cellular Therapies in Early Relapsed Multiple Myeloma?
Joseph Mikhael, MD
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Guy Young, MD
Diving into the Efficacy & Tolerability of mBC Treatment
Pavani Chalasani, MD, MPH
Colleen Bohnenkamp, PharmD, BCPS, BCOP
Metastatic TNBC: Utilizing Biology and Health Disparities to Inform Shared Decision Making
Sara A. Hurvitz, MD, FACP
How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
Sara M. Tolaney MD, MPH
What Is the Future of ADCs in Metastatic TNBC?
ADC Targets: Does Positivity Really Matter?
What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?
Which TNBC Patients Are Eligible for ADCs?
What Is the Evidence for ADCs in HR-/HER2-Low Metastatic Breast Cancer?
Triple-Negative Breast Cancer (TNBC): Choosing the Right ADC for the Right Patient
How Are We Addressing Unanswered Questions Around ADCs in Metastatic TNBC?
What Do Patients/Caregivers Need To Know About ADCs in Metastatic TNBC?
A Changing Approach to TNBC Management: Patients as Partners in Care
Tiffany Traina, MD, FASCO
Gregory Vidal, MD, PhD
Stephanie Walker, RN
Reducing the Rise of Uterine Cancer in the United States
Charles Turck, PharmD, BCPS, BCCCP
Richard T. Penson, MD, MRCP
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
Alex Herrera, MD
Alison J. Moskowitz, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.